MedWatch

Orphazyme hires medical expert to convince doctors of lead candidate's potential

Danish biotech company Orphazyme has employed a medical expert with experience from various major drug groups as head of Orphazyme’s Medical Affairs function. The main objective is to spread information about the company’s candidate drug.

Foto: Thomas Lekfeldt/STF

Danish biotech company Orphazyme recently got a big step closer to an approval of the company’s only candidate, arimoclomol, against the metabolic Niemann-Pick disease, type C.

After receiving fresh data from the first phase III study in September 2018, Orphazyme announced that the company would “immediately initiate filing preparations and seek to meet with the FDA and EMA mid-2019 to discuss the path to approval.”

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier